[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hirota et al., 2016 - Google Patents

Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeys

Hirota et al., 2016

View PDF
Document ID
887431535637128676
Author
Hirota M
Murakami I
Ishikawa Y
Suzuki T
Sumida S
Ibaragi S
Kasai H
Horai N
Drolet D
Gupta S
Janjic N
Schneider D
Publication year
Publication venue
Nucleic acid therapeutics

External Links

Snippet

Interleukin-6 (IL-6) is a potent mediator of inflammatory and immune responses, and a validated target for therapeutic intervention of inflammatory diseases. Previous studies have shown that SL1026, a slow off-rate modified aptamer (SOMAmer) antagonist of IL-6 …
Continue reading at www.liebertpub.com (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Similar Documents

Publication Publication Date Title
Hirota et al. Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeys
Sivamani et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring
EP3111954B1 (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies
US11008393B2 (en) Pharmaceutical compositions comprising a polypeptide that binds to IL-6
Taylor Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases
EP3119806B1 (en) Il-21 antibodies
JP5834004B2 (en) Methods and compositions for lupus treatment
RU2714919C2 (en) Gm-csf-neutralizing antibodies for use in treating rheumatoid arthritis or as analgesics
JP2015524793A (en) Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3, and anti-CXCR5 agonists for inflammation inhibition
TW201429988A (en) Antibodies to interleukin-6 and uses thereof
US20180113139A1 (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders
Liu et al. Interleukin-6 in rheumatoid arthritis-from the laboratory to the bedside
Zhou et al. Plasmacytoid dendritic cells promote the pathogenesis of sjögren's syndrome
JP2023542878A (en) LOU064 for treating multiple sclerosis
AU2008324800B2 (en) Methods of treating scleroderma
Berkhout et al. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment
WO2018029182A1 (en) Il-6r single variable domain antibodies for treatment of il-6r related diseases
TW202106712A (en) Methods of diagnosis and treatment of rheumatoid arthritis
Reimund et al. Anti-Tumor Necrosis Factor-alpha (TNF-α) Treatment Strategies in Crohn's Disease
AU2014259523B2 (en) Methods of treating psoriatic arthritis using IL-17 antagonists
Hirabayashi et al. The role of tocilizumab in the treatment of rheumatoid arthritis
Sozeri et al. Canakinumab: new treatment choice for systemic juvenile idiopathic arthritis
Ellies et al. Adipose tissue macrophage Diet-induced obesity Free fatty acid GPCR HFD
WO2017064564A2 (en) Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody
JP2019515902A (en) Functional plasticity of ILC2, immunity, and COPD